Addex TherapeuticsADXN
About: Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
Employees: 23
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
680% more capital invested
Capital invested by funds: $13.6K [Q3] → $106K (+$92.2K) [Q4]
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
67% more funds holding
Funds holding: 3 [Q3] → 5 (+2) [Q4]
0.01% more ownership
Funds ownership: 0% [Q3] → 0.01% (+0.01%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for ADXN.
Financial journalist opinion









